Patient Characteristics (n = 388)
| Characteristic | Data |
| Initial PSA at diagnosis | |
| Median (ng/mL) | 8.9 |
| Range (ng/mL) | 0.7–2,086 |
| <10 ng/mL (n) | 144 (37%) |
| ≥10 to < 20 ng/mL (n) | 56 (14%) |
| ≥20 ng/mL (n) | 55 (14%) |
| Unknown (n) | 133 (34%) |
| Gleason score (n) | |
| ≤7 | 163 (42%) |
| ≥8 | 150 (39%) |
| Unknown | 75 (19%) |
| Primary tumor stage (n) | |
| T1–T2 | 79 (20%) |
| T3–T4 | 96 (25%) |
| Unknown | 213 (55%) |
| Initial NCCN risk group (n) | |
| Low | 29 (7%) |
| Intermediate | 102 (26%) |
| High | 194 (50%) |
| N1 | 18 (5%) |
| Unknown | 45 (12%) |
| Prior treatment (n) | |
| Primary surgery | 227 (59%) |
| Surgery only | 126 (32%) |
| Surgery + ADT | 13 (3%) |
| Surgery + SRT ± ADT | 52 (13%) |
| Surgery + PLND ± ADT | 3 (1%) |
| Surgery + SRT + PLND + ADT | 1 (0%) |
| Surgery + chemotherapy ± ADT | 32 (8%) |
| Primary RT | 55 (14%) |
| RT only | 35 (9%) |
| RT + ADT | 13 (3%) |
| RT + chemotherapy ± ADT | 7 (2%) |
| Age at PET/CT (y) | |
| Median | 69 |
| Range | 39–95 |
| Time between primary treatment and PET/CT (mo) | |
| Median | 161 |
| Range | 0.75–794.50 |
| Ongoing systemic therapy (n) | 70 (18%) |
| Last serum PSA before PET/CT (ng/mL) | |
| Median | 3.66 |
| Range | 0.04–1,776.79 |
| Indication for PET/CT (n) | |
| Initial staging | 93 (24%) |
| Biochemical recurrence localization | 225 (58%) |
| Restaging M1 | 70 (18%) |
ADT = androgen deprivation therapy; SRT = salvage radiation therapy; PLND = pelvic lymph node dissection; RT = radiation therapy.